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AbstrACt
Introduction Prostate cancer is the most common male 
cancer with one in four developing non- curable metastatic 
disease. Initial treatment responses to hormonal therapies 
are transient and further management options lie between 
(1) further hormone therapy or (2) a non- hormonal 
approach involving additional chemotherapy or molecular 
radiotherapy (radium-223). There is no clear rationale 
for choosing between these mechanistically different 
treatment approaches. The biology of hormone resistance 
is driven through abnormal androgen receptor activity 
and we can assay this through a blood test measuring 
androgen receptor variant 7 (AR- V7) expression in 
circulating tumour cells. Despite increasing evidence 
supporting AR- V7’s role as a prognostic marker, the clinical 
utility of such measures remains unknown in helping 
personalise treatment decisions.
Methods and design The VARIANT feasibility trial is 
a pragmatic design, to be run over 18 months with 
participants randomised into the intervention arm 
receiving biomarker (AR- V7) guided clinical treatment 
and participants randomised into the control arm with 
conventional standard management (no biomarker 
guidance). AR- V7 positive participants (likely to be 
insensitive to further hormone treatment) will receive 
chemotherapy or in other cases radium-223 (where 
routinely available). Seventy male ≥18 years old 
participants with metastatic castrate resistant prostate 
cancer clinically indicated to proceed to further hormone 
therapy or chemotherapy, will be recruited from three 
National Health Service Trusts based in England, Scotland 
and Wales. The feasibility primary outcome is willingness 
of patients to be randomised and clinicians to recruit to 
a biomarker- based treatment strategy, with trial data 
informing the basis of a definitive and appropriately 
powered randomised control trial.
Ethics and dissemination Formal ethics review was 
undertaken with a favourable opinion, through Wales NRES 
Committee 2 18/WA/0419. Findings to be disseminated 
through patient and professional organisations that have 
expressed their support, media outlets and peer- reviewed 
journal publication.
trial registration number ISRCTN10246848; pre-results
strengths and limitations of this study
 ► Focuses on a priority area of need in advanced pros-
tate cancer clinical practice.
 ► To date, the feasibility of delivering a randomised 
biomarker guided- treatment trial in prostate cancer 
to formally assess clinical utility is not established 
and will be addressed in this study.
 ► As a feasibility study, the planned sample size (70 
participants) does not have sufficient power or pre-
cision to compare the ‘event’ rate between treat-
ment arms, but will allow informed planning for a 
definitive randomised controlled trial with prominent 
clinicians from non- recruiting centres involved in 
feasibility, to aid with follow- on trial.
 ► Emerging evidence points to additional androgen 
receptor biology driving hormone resistance, such 
as other variant expression and mutations — these 
along with alternative biomarkers can be explored in 
the associated biobanked samples (including cell- 
free tumour DNA).
 ► Strong patient and public involvement (PPI) to inform 
study design with a clear commitment to informing 
participants of project outcomes, setting a clear new 
gold standard for PPI.
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IntroduCtIon
background
Prostate cancer (PC) is the most common male cancer 
in the UK and the second highest cause of male cancer 
death.1 In large part, PC is a slowly progressive disease 
and when detected at an early stage is managed by 
active surveillance, surgery or radiotherapy. However, 
25% of patients will present with, or will progress to, 
advanced metastatic PC.2 3 Metastatic PC is incurable, 
with less than one- third of the patients surviving more 
than 5 years.1
Medical castration (commonly referred to as hormonal 
treatment or androgen deprivation therapy (ADT)), 
blocks production of the hormone testosterone and/or 
targets the androgen receptor (AR) signalling axis that 
drives cancer cell growth. Although a good response to 
hormonal treatment seen often initially, disease progres-
sion to a lethal metastatic castration- resistant pros-
tate cancer (mCRPC) is common.4 Clinical trials have 
shown that the addition of chemotherapy (docetaxel) 
or other hormonal approaches (abiraterone acetate 
or enzalutamide) to initial hormonal therapy have 
led to a substantial improvement (ie, delay) in time 
to the development of mCRPC and overall survival 
(OS).5–9 Furthermore, promising recent evidence from 
randomised trials of androgen- receptor axis- targeted 
drugs (ARATs) have shown addition of apalutamide 
(an inhibitor of the ligand- binding domain of the AR), 
alongside hormone therapy results in longer overall 
survival and radiographic progression free survival 
compared with placebo.10 However despite these rapid 
advances, mCRPC typically manifests within 3 years and 
is uniformly fatal.11–13
treatment management for mCrPC
Management pathways for mCRPC are still evolving in 
response to emerging new treatments; however, it broadly 
follows one of two standard care approaches;14 (1) further 
hormonal treatment such as abiraterone or enzalutamide 
or (2) ‘non- hormonal’ treatment, typically chemotherapy 
or molecular radiotherapy (radium 223) (where avail-
able). There is no clear biological rationale for choosing 
between these mechanistically different treatment 
approaches. Suitable patients for this study can receive 
both approaches in a sequential manner if one is failing. 
Patients and clinicians often prefer hormonal treatment, 
being less toxic and easier to manage, however, only 30% 
to 50% of men respond well, with the remainder demon-
strating a poor or an equivocal response.15 16 As many 
patients will not respond to either treatment approach, 
there are considerable costs from our current manage-
ment pathways, both in terms of patient experience and 
outcomes (side effects and disease progression) and 
economic costs to the National Health Service (NHS) 
(large burden of expensive treatments for the the most 
common male cancer). Personalised management path-
ways are urgently needed.
biology of the androgen receptor (selective treatment 
pressure)
A breakthrough in understanding the biology of PC 
revealed that hormonal treatments generate a selective 
pressure at the cellular level inducing complex molec-
ular mechanisms characterised by an adaptation of the 
AR signalling axis. This results in tumour resistance medi-
ated by the induced expression of alternative types of 
androgen receptor. These AR messenger RNA (mRNA) 
splice variants lack the important hormone- binding 
domain, resulting in a constitutively active cellular 
receptor, despite castration. The most widely studied 
variant is androgen receptor variant 7 (AR- V7).17 18 AR- V7 
activity is not affected by ‘hormonal treatment’ such as 
enzalutamide and abiraterone that target the hormone- 
binding domain, potentially rendering these treatments 
ineffective in men with AR- V7.19–21 A surge in ARATs avail-
able for clinical use (eg, apalutamide and darolutamide) 
will most likely enhance this burden (although of note, 
evidence demonstrating reduced effectiveness of these 
specific treatment in men who are positive for AR- V7 or 
other variant splice forms including AR point mutations, 
have not been published to date).
rationale
Published clinical data demonstrates a strong link between 
AR- V7 expression and mCRPC progression and highlights 
the potential for AR- V7 to be utilised as a treatment stratifi-
cation biomarker to identify those men likely to be sensitive 
to further hormonal treatment (AR- V7 negative patients) 
and avoid futile treatments in those predicted to be insensi-
tive (AR- V7 positive patients).21–29 Notably AR- V7 positivity 
is not associated with insensitivity to taxane chemotherapy 
treatment (relative reduction in risk of death of 76% 
maintained with chemotherapy, HR: 0.24; 95% CI 0.10 to 
0.57; p=0.035)27 30 and data from the recent PROPHECY 
trial (Multicenter Prospective Trial of Circulating Tumor 
Cell AR- V7 Detection in Men with mCRPC Receiving 
Abiraterone or Enzalutamide, NCT02269982), reports on 
the prognostic value of the AR- V7 biomarker (prospec-
tive observational cohort of poor prognosis patients with 
advanced prostate cancer who receive abiraterone or 
enzalutamide treatment).30 The commercially available 
AdnaTest ProstateCancerPanel AR- V7 assay (Qiagen) 
detects AR- V7 mRNA expression in circulating tumour cells 
(CTCs) in whole blood and has been independently and 
robustly clinically validated in terms of reproducibility and 
comparisons of sensitivity and specificity with other AR- V7 
detection platforms.31–33 However to date, there have been 
no formal measures of the clinical utility of AR- V7 as a 
predictive biomarker.
Evidence gap
Encouragingly, a cost saving analysis of performing 
AdnaTest ProstateCancerPanel AR- V7 biomarker testing in 
mCRPC demonstrated use of the biomarker would result 
in a substantial cost saving as long as the true prevalence of 
AR- V7 was >5% (well below the accepted prevalence rate of 
 o
n
 February 21, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034708 on 18 December 2019. Downloaded from 
3Clark E, et al. BMJ Open 2019;9:e034708. doi:10.1136/bmjopen-2019-034708
Open access
30%).34 However, formal cost- effectiveness analyses based 
on incremental cost- effectiveness ratio (cost per quality- 
adjusted life year gained) and assessing prevalence rates of 
this biomarker have yet to be carried out.
The National Comprehensive Cancer Network Task 
Force35 and Cancer Research UK (CRUK) consensus 
statement on biomarker roadmap for cancer studies,36 
have highlighted the key recommendations for accel-
erating a tumour biomarker into clinical practice by 
sequentially demonstrating evidence for; [1] analytical 
reproducibility; [2] clinical validity and [3] clinical utility. 
Previous clinical studies on AR- V7 testing focused on 
retrospective or prospective cohort analyses of associated 
AR- V7 expression distinguishing subgroups with different 
clinical outcomes with hormonal treatment in men with 
metastatic PC.37–40 However, the highest level of assess-
ment of clinical worth in improving patient outcomes 
(clinical utility) remains lacking. We have paid partic-
ular focus to address clinical utility evidence gaps in the 
VARIANT trial using published levels of evidence stan-
dards for assessing biomarkers to inform study design.41 42 
We aim to demonstrate improvement in patient outcome 
sufficiently to justify AR- V7 biomarker incorporation into 
routine clinical care (including feasibility of collecting 
quality of life measures for a future health economic 
evaluation).
Emerging treatment landscape
The treatment landscape of hormone sensitive (PC) is 
evolving, altering treatment pathways for mCRPC. Recent 
data from the USA based PROPHECY trial reporting 
on a prospective observational cohort showed mRNA 
AR- V7 (modified Qiagen AdnaTest ProstateCancerPanel, 
Baltimore, Maryland) and protein AR- V7 (Epic nuclear- 
specific, San Diego) biomarker positivity associated with 
worse progression free survival and OS in poor prog-
nosis patients with advanced prostate cancer who receive 
abiraterone or enzalutamide treatment.30 Criticisms of the 
study included lack of testing with alternative treatment 
such as chemotherapy (which we have addressed in this 
study) and preselection of high risk CRPC patients (ie, 
those with poor prognosis), ultimately generating results 
that cannot be extrapolated over the overall CRPC popu-
lation.43–46 Of note, lower AR- V7 prevalence was reported 
in the overall CRPC population in the ARMOR3- SV phase 
III clinical trial which employed the AdnaTest Prostate-
CancerSelect and detect CTC assay (Qiagen) to assess 
AR- V7 mRNA expression, where only 8% of men were 
AR- V7 positive (95% CI 6 to 10).47 48 During reviewing 
of this protocol, results of the CARD trial (Cabazitaxel 
vs Abiraterone or Enzalutamide in Metastatic Prostate 
Cancer) were published showing median overall survival 
was 13.6 months with cabazitaxel and 11.0 months with 
androgen signalling targeted inhibitors (HR for death, 
0.64; 95% CI 0.46 to 0.89; p=0.008). CARD investigators 
plan to analyse CTCs for AR- V7 in order to determine the 
prognostic and predictive value of CTC- derived AR- V7 
detection, further contributing important findings from 
this evolving treatment landscape.49
We argue irrespective of the evolving treatment land-
scape, the opportunity to generate feasibility data for a 
biological (biomarker) informed approach to treatment 
selection over standard care protocol- based approaches, 
tests a highly relevant clinical question in these high risk 
CRPC patients (ie, those who have more to loose from 
pursuing a ‘try and see’ approach). This would provide 
an appealing long- term strategy (for patients and service 
providers) to ultimately improve on clinical outcome 
(specifically for a clinical subgroup of poor prognosis 
patients, identifying those likely to be sensitive to further 
hormonal treatment and avoid futile treatments in those 
that are predicted to be insensitive).
Main aim of study
To determine the feasibility of conducting a definitive 
randomised control trial to evaluate the clinical utility of 
an AR- V7 blood biomarker assay in personalising treat-
ment for men with mCRPC in UK NHS clinical practice.
objectives
Feasibility study.
Primary objective
1. To establish if it is feasible to conduct a definitive trial 
comparing AR- V7 biomarker- driven management with 
the current standard care in patients with mCRPC.
Secondary objectives
2. To estimate AR- V7 biomarker prevalence in the trial 
population to inform sample size calculations for a de-
finitive randomised control trial.
3. To assess recruitment, compliance and retention rates.
4. To confirm outcome measures for a future definitive 
trial and establish trial data response rates, variability 
and data quality.
5. To establish a blood sample biorepository to include 
baseline, 12 and 24 week blood samples for future 
translational studies.
Exploratory objectives
6. To establish a complete serial blood tissue archive to 
include potential measures of cell- free DNA (cfDNA) 
and additional AR variants in CTCs and cfDNA bio-
marker measures to complement AR- V7 reads (such as 
AR mutations, other AR splice forms and AR ampli-
fication, and other mutations such as PTEN,p53,MYC 
gain,RB1 loss,MET gain and further molecular path-
ways yet to be defined), depending on the ultimate 
biomarker performance characteristic established in 
this trial population. Blood will be collected, processed 
and archived at 0 weeks (baseline), 12 weeks and 24 
weeks following the first treatment.
7. To explore thresholds of the magnitude of AR- V7 pos-
itivity to investigate relationships with outcomes and 
estimate AR- V7 positivity rate assumptions regarding a 
cut- off point.
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Figure 1 VARIANT trial Consolidated Standards of Reporting Trials diagram. Planned flow of participants throughout the 
VARIANT study. AR- V7, androgen receptor variant 7; EORTC- QLQ- C30/PR25, European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire; mCRPC, metastatic castrate resistant prostate cancer; PSA, prostate specific 
antigen.
8. To undertake cross- site validation of biomarker reads 
between two GCP laboratories (Newcastle University 
and Cardiff University).
MEthods And AnAlysIs
study design
This feasibility study is a multicentre, two- arm, randomised 
control trial (RCT). All patients who consent to take part 
in the trial and who are eligible, will have a blood test 
to assess prevalence rate of the AR- V7 biomarker. Partici-
pants will be randomised in the ratio 1:1 to receive person-
alised standard treatment (intervention) guided by AR- V7 
biomarker status or standard care (control) without 
biomarker- guided treatment. Those in the control group 
will not receive blood biomarker test results.
The treatment for each patient is expected to be depen-
dent on various factors (eg, clinician choice, patient 
choice, previous treatments, comorbidities, concomitant 
medication and pattern of disease), as well as randomised 
allocation and AR- V7 status in the personalised treat-
ment arm. All treatments are part of standard care for 
these participants. Treatment options for participants 
randomised to the personalised standard treatment 
arm will be recommended, but not mandated within 
this feasibility trial, with reasons for not following the 
recommendation recorded and reported as outcome. A 
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Consolidated Standards of Reporting Trials diagram of 
study protocol (V.2.0, 8 March 2019) is shown in figure 1.
study setting
Seventy patients with mCRPC who require a change in 
treatment will be recruited in three secondary care NHS 
Trusts in the UK spread across England (The Newcastle 
upon Tyne Hospitals NHS Foundation Trust), Scotland 
(NHS Greater Glasgow and Clyde) and Wales (Velindre 
University NHS Trust). We aim to recruit mCRPC patients 
with a predicted poor overall survival. We anticipate this 
group of mCRPC patients have the most to gain from a 
biological- based treatment approach as their disease is 
more likely to progress during a period of treatment with 
an inactive agent. Multivariate analysis from the meta-
static population of STAMPEDE50 (Systemic Therapy 
in Advancing or Metastatic Prostate Cancer: Evaluation 
of Drug Efficacy a multi- arm multi- stage randomised 
controlled trial, NCT00268476), has shown that worse 
overall survival was seen in men with the following 
features: presence of bone metastases (regardless of soft 
tissue metastases), worse WHO performance status (0 vs 
1 or 2), higher (or unknown) initial Gleason sum score 
category (≥8 vs ≤7) and younger age at randomisation 
<60 years. Poorer failure free survival (but not overall 
survival was additionally seen in men with worse primary 
tumour stage and higher PSA level before starting 
ADT. There is overlap between these poor prognostic 
features and factors associated with a high likelihood of 
harbouring AR- V7 positive CTCs.33 40 51
Eligibility criteria
Patients will be aged ≥18 years old with metastatic castrate 
resistant prostate cancer (high risk features) clinically 
indicated to proceed to further hormone therapy or 
chemotherapy and fulfil all of the following criteria:
1. Histologically or cytologically proven diagnosis of ade-
nocarcinoma of the prostate.
2. Radiographic and/or histological and/or cytological 
evidence of metastatic disease.
3. Castrate levels of testosterone and documented ongo-
ing medical or surgical castration. Testosterone level 
≤50 ng/dL/1.73 nmol/L and maintaining on andro-
gen suppression therapy.
4. Disease progression since the last change in therapy 
defined by one or more of the following: (i) PSA pro-
gression as defined by the prostate cancer working 
group 3 criteria ≥2 ng/mL; (ii) bone disease progres-
sion as determined by the local radiology/multidisci-
plinary team; (iii) radiographic progression of nodal 
or visceral metastases as determined by the local radiol-
ogy/multidisciplinary team.
5. Suitable for treatment with at least one novel hormon-
al treatment (with available treatments abiraterone ac-
etate or enzalutamide) and one non- hormonal thera-
py (with available treatments docetaxel, cabazitaxel or 
radium-223).
6. At least two high risk features: (i) age <60 years at time 
of diagnosis of metastatic disease; (ii) bone metasta-
ses present at time of initial metastatic prostate cancer 
diagnosis (although not mandated, it is considered 
good clinical practice to have up to date imaging with-
in 8 weeks); (iii) Gleason grade group 4 or 5 (Glea-
son score 8 to 10); (iv) presence of visceral metastases 
(eg, liver or lung) at any time point. This does not in-
clude lymph node metastases; (v) PSA doubling time 
<3 months; (vi) elevated alkaline phosphatase above 
institutional upper limit of normal; (vii) Eastern Co-
operative Oncology Group (ECOG) Performance Sta-
tus worse than or equal to 1; (viii) previous treatment 
for castration resistant prostate cancer with docetaxel 
chemotherapy; (ix) previous treatment for castration 
resistant prostate cancer with abiraterone and/or en-
zalutamide or equivalent agent.
7. Estimated life expectancy >6 months.
8. Provision of written informed consent, including con-
sent for biobanking of blood samples.
Exclusion criteria applied in the VArIAnt trial are
1. Histological variants of prostate cancers with small cell 
or neuroendocrine features.
2. Prior or current malignancy (except adenocarcinoma 
of the prostate) with an estimated ≥30% chance of re-
lapse/progression within next 2 years.
3. Previously identified brain metastases or spinal cord 
compression unless treated with full functional recov-
ery.
4. Administration of an investigational agent within 30 
days of first dose of trial medication.
randomisation
Patients will be randomised to receive either personalised 
standard treatment (guided by AR- V7 biomarker status) 
or standard care (not guided by biomarker status) on a 
1:1 basis using a method of random permuted blocks of 
concealed variable block size and stratified by site.
study intervention
This three- centre randomised feasibility study incorpo-
rates a control and an intervention arm. All patients will 
undergo AR- V7 biomarker assessment with results only 
made known to the patients and clinical team in the inter-
vention arm.
Intervention arm
Treatment will be given as per standard care with recom-
mendations guided by biomarker status; [1] if the partic-
ipant is found to be AR- V7 positive, then non- hormonal 
treatment is recommended (docetaxel chemotherapy, 
cabazitaxel chemotherapy or radium-223 therapy) or; [2] 
if the participant is found to be AR- V7 negative, then next 
generation hormonal treatment is recommended (either 
enzalutamide or abiraterone).
The results of the AR- V7 biomarker assessment will be 
provided securely to the clinical team to enable tailored 
treatments based on AR- V7 expression from the biomarker 
 o
n
 February 21, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034708 on 18 December 2019. Downloaded from 
6 Clark E, et al. BMJ Open 2019;9:e034708. doi:10.1136/bmjopen-2019-034708
Open access 
box 1 standardised clinical assessment tools
Clinical outcome measures
1. Time to PSA progression; Confirmed rising PSA more than 12 weeks 
after randomisation. (Where there has been a decline in PSA from 
baseline, progression will be a 25% or greater increase, and an ab-
solute increase of at least 2 ng/mL, from the nadir, which is con-
firmed by a second value obtained 3 or more weeks later. Where no 
decline from baseline is documented, progression must be a 25% 
or greater increase from the baseline value along with an increase 
in absolute value of 2 ng/mL or more. In all cases, the initial rise in 
PSA must occur after a minimum of 12 weeks from randomisation).
2. Clinical progression and survival within 6 months; (i) Number of pa-
tients who have progressed clinically at 6 months (includes change 
of systemic anti- cancer therapy and death from prostate cancer); 
(ii) Cancer specific survival at 6 months and (iii) overall survival at 
6 months.
3. Quality of life for patients with cancer (EORTC QLQ- C30 
Questionnaire).
4. Additional quality of life items patients with prostate cancer (EORTC 
QLQ- PR25 Questionnaire).
5. Participant costs questionnaire (Use of Health Services 
Questionnaire).
result. Where a decision is made that the participant will 
receive a non- recommended therapy (either by the clini-
cian or patient) this therapy, and the reasons for giving 
this, will be documented.
Control arm
Participants with their clinical care team will make an 
informed and preference- based decision to receive stan-
dard care, including either next generation hormone 
treatments abiraterone or enzalutamide or non- hormonal 
approaches including docetaxel or cabazitaxel chemo-
therapy or radium-223. Details of all treatment admin-
istered, including doses, will be recorded as part of the 
trial.
The research team at sites will not receive the partici-
pants AR- V7 biomarker results.
outcome measures
Standardised clinical assessment tools used in monitoring 
CRPC disease and progression on treatment will be 
reported (listed in box 1). Primary outcome measures are 
related to feasibility (recruitment, retention and adher-
ence) and will report the following;
1. The proportion of prostate cancer patients identified 
through clinics who meet the eligibility criteria.
2. The number of patients accrued per site per month 
over the course of the trial.
3. Baseline prevalence of AR- V7 expression in the par-
ticipant cohort (this will be presented as a crude per-
centage of AR- V7 positivity of total participants, and in 
each arm).
4. The willingness of patients to be randomised (defined 
as the proportion of patients consenting to be ran-
domised from all eligible patients approached about 
the study).
5. Compliance rate (this will be defined as the number of 
patients who start randomised treatment as a propor-
tion of the number randomised).
6. The proportion of patients who: start AR- V7 recom-
mended treatment; start treatment other than the 
recommended treatment; change treatment before 
disease progression or withdraw. (This measure will 
capture information regarding patients who choose 
not to take recommended treatment because of strong 
preferences and patients who progress rapidly while 
waiting for treatment with a change in eligibility for 
treatment options).
7. The proportion of trial participants with assessable 
blood samples for biomarker status (which would af-
fect treatment targeting).
8. The median time from the blood sample being drawn 
to; (i) AR- V7 result being sent back to the site and (ii) 
patient starting treatment (and compared with stan-
dard of care treatment).
9. The proportion of randomised patients for whom data 
is collected on each clinical and health economic out-
come at baseline, 12 and 24 weeks.
Further information on recruitment, screening, the 
patient consent procedure and informed consent litera-
ture, can be found in the online supplementary section.
data collection
Table 1 shows a trial schedule of events. A more detailed 
description of all data collection including a data manage-
ment plan, can be found in the online supplementary 
section. In summary, in addition to collecting standard 
care assessment of disease status data from patients in 
the intervention and control arms, trial specific question-
naire assessment (EORTC- QLQ- C30 Quality of Life of 
Cancer Patients, EORTC- QLQ- PR25 Quality of Life Pros-
tate Cancer Module), will take place at the baseline, 12 
and 24 week visit.
Ar-V7 biomarker measure
A validated two- centre pipeline (consisting of preanalyt-
ical, analytical and postanalytical phases) to measure AR- V7 
biomarker using the commercially available AdnaTest 
ProstateCancerPanel AR- V7 circulating tumour cell quan-
titative RT- PCR assay (Qiagen, intended for molecular 
biology applications), has been set up according to assay 
manufacturers recommendations, analytical methods 
and sponsor agreed Standard Operating Procedures 
(SOP's). Following biomarker data analysis and data 
verification, for participants randomised to the interven-
tion standard treatment arm (AR- V7 biomarker guided), 
the baseline biomarker result and biomarker treatment 
recommendation will be sent securely within 10 working 
days to the local principal investigator and delegated 
research staff. Further information on the specifics of 
AR- V7 biomarker driven personalised treatment (sample 
receipt, processing, analysis and reporting of read- out), 
can be found in the online supplementary section.
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Table 1 Trial schedule of events
Procedure Screening Visit 1
consent/
baseline
Visit 2
12 
weeks
(+/-2 
weeks)
Visit 3
24 
weeks
(+/-2 
weeks)
Medical history and 
demographics
X
Record results of standard 
care PSA test
X X X X
Eligibility assessment X* X*
Patient information sheet X
Informed consent X
Testosterone if no previous 
confirmation
X†
Confirmation of eligibility X*
Randomisation X
Access to standard of care 
haemoglobin and biochemistry 
results
X
Blood sample collection and 
shipment for CTC/ctDNA 
blood assessment and AR- 
V7 analysis (analysed at 
Newcastle University Central 
Analysis Lab)
X X X
CTC blood sample collection 
and shipment for cross- site 
validation‡ (analysed at Cardiff 
University Central Analysis 
Lab)
X‡
EORTC QLQ- C30/PR25 
Questionnaires
X X
AR- V7 blood test result 
feedback to patient§
X§
Use of Health Services 
Questionnaire
X
Anti- cancer therapy review X X
Clinical assessment of disease 
status
X X
*Eligibility assessment performed against trial eligibility criteria in screening, patients 
likely to be eligible will be given a VARIANT information sheet and trial information. 
Eligibility will be confirmed by an Investigator (medically qualified doctor) after patients 
have provided written informed consent and before randomisation.
†In those cases where there is no previous confirmation of castrate levels of 
testosterone only. These patients will not be randomised until castration is confirmed 
and the patient is documented as eligible.
‡For selected patients only (confirmed at randomisation), for cross- site validation of 
AR- V7 status.
§For patients randomised to the personalised standard treatment arm (guided by 
AR- V7 biomarker) only.
AR- V7, androgen receptor variant 7; CTC, circulating tumour cells; ctDNA, circulating 
tumour DNA; EORTC- QLQ- C30/PR25, European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire; PSA, prostate specific antigen.
data analysis plan
Analyses will be conducted on an intention- to- treat basis, 
with sensitivity analyses used to investigate the impact of 
non- compliance to allocated arm. Given the feasibility 
status of this study, all statistical analyses will be descrip-
tive. The majority of the outcome data will be presented in 
simple descriptive tables presenting percentages, means 
and SD or five- number summary (as appropriate), for 
each arm of the study. Analysis of clinical and biomarker 
measures will be assessed by; [1] clinical progression 
and survival within 6 months; [2] PSA response/progres-
sion (confirmed rising PSA more than 12 weeks after 
randomisation); [3] clinical progression and survival 
(overall and cancer specific) within 6 months (includes 
change of cancer therapy for progression) and; [4] 
survival (overall and progression free) estimates will be 
derived using the Kaplan- Meier method and presented as 
6 month rates with CIs. The relationship between survival 
estimates and continuous AR- V7 biomarker expression 
will be modelled considering non- linear transformations 
in a univariate Cox model, or parametric alternative, 
presented as parameter estimates (HR) with CIs.
Compliance with quality of life and health economic 
measures will be assessed by; [1] number of patients 
completing measures as a proportion of the number 
randomised and; [2] degree of completeness of each 
domain of the European Organisation for Research 
and Treatment of Cancer Quality of Life Questionnaire 
(EORTC- QLQ) and economic questionnaire measures. 
These scores will be presented graphically and with numeric 
descriptive statistics.
study statistical size calculations
This trial is designed as feasibility trial according to defi-
nition of Eldridge et al.52 Feasibility includes the deliver-
ability of the intervention and in this case, assessment of the 
frequency of the positive assay measurements (predicted at 
approximately 30%). It has been recommended that data 
in an external pilot trial is collected on a minimum of 60 
patients per arm to estimate the ‘event’ rate.53 However, we 
plan to calculate a pooled estimate of overall recruitment 
rate, and overall biomarker prevalence rate, and will recruit 
70 patients in total to allow for attrition.
The performance of potential outcome measures for a 
definitive trial will be assessed by estimating data complete-
ness of the instruments and any potential bias in the comple-
tion of follow- up data. This information will be used to 
inform the design, choice of outcomes, necessary sample 
size and approach to the analysis, of a future definitive trial.
safety reporting
This is a low risk trial and no specific safety reporting 
is required. Should an Investigator have any concern 
regarding participant safety as an outcome of their partic-
ipation in the trial, they will contact the Trial Manage-
ment Group (TMG) and Chief Investigator as soon as 
possible. The Trial Oversight Committee (TOC) will 
monitor concerns as required.
trial conduct and governance
The trial will be conducted in accordance with the UK 
Policy Framework for Health and Social Care and as 
applicable, the Guidelines for Good Clinical Practice. 
The TMG is responsible for the day- to- day management 
of the trial, overseeing all aspects of the conduct of trial 
to ensure that the protocol is adhered to and take appro-
priate actions to ensure patient and data safety. The 
TOC will review trial conduct and accumulating clinical 
trial data and provide overall supervision for the trial on 
behalf of the Sponsor and the Funder. The constitution 
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of the TMG and TOC including roles and responsibilities 
delegation for this trial can be found in the online supple-
mentary section. Aggregated data will be analysed by the 
Trial Statisticians and reported to an external indepen-
dent TOC at least annually.
Public and patient involvement
The design, planning and management of this trial has 
been supported by two prostate cancer patient repre-
sentatives (co- applicant on the funding grant and TMG 
member). Both have advocated the dissemination of 
trial findings to patients and ensured that the public was 
adequately considered during trial design. PPI has been 
embedded into the study, with the patient’s voice a strong 
theme to inform and influence the ongoing research 
and development of participant information resources 
in collaboration with the ‘Cancer Perspectives’ patient 
representative group (Newcastle upon Tyne Hospitals 
NHS Foundation Trust). A strong commitment is to 
inform the participants of the outcome of this project, a 
clear new gold standard for PPI.
Ethics and dissemination
All parties will conduct the trial in accordance with 
ethical opinion. No amendment to protocol will be made 
without consideration and approval by the Trial Manage-
ment Committee.
Feasibility data will be published as a peer- reviewed 
article and if successful, these findings will contribute to 
gaining further funding for a HTA full trial. In addition, 
assessing clinical data and blood derivatives from the 
participant cohort will provide valuable material (circu-
lating tumour cells transcript and plasma circulating 
tumour DNA), to validate translational studies of other 
AR aberrations and hormone targeting resistance path-
ways (or the emergence of biomarkers for chemosensi-
tivity), to inform and contribute further to the rapidly 
evolving treatment developments for CRPC. Participants 
will remain anonymised in all publications.
We will also use dissemination through patient and 
professional organisations that have expressed their 
support for this trial (PCF, CRUK, NCRI Prostate CSG 
and BAUS) and through media outlets including web 
resources, lay press, academic national and international 
conferences and peer- reviewed journal publication.
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